tasimelteon 20 mg capsule + tasimelteon 2 mg I.V.
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-24-Hour-Sleep-Wake Disorder
Conditions
Non-24-Hour-Sleep-Wake Disorder
Trial Timeline
May 1, 2014 → May 1, 2014
NCT ID
NCT02130999About tasimelteon 20 mg capsule + tasimelteon 2 mg I.V.
tasimelteon 20 mg capsule + tasimelteon 2 mg I.V. is a approved stage product being developed by Vanda Pharmaceuticals for Non-24-Hour-Sleep-Wake Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02130999. Target conditions include Non-24-Hour-Sleep-Wake Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02130999 | Approved | Completed |